Has 4DMedicals Stock Skyrocketed Again on Big Clinical Win?
Source: Kapitales Research
Highlights:
4DMedical Limited (ASX: 4DX) jumped 16% after UC San Diego Health began clinical use of its CT:VQ lung imaging technology.
It is now the fourth major US academic medical centre to deploy CT:VQ since the technology received FDA clearance.
The growing adoption strengthens investor confidence in CT:VQ becoming a new standard for advanced pulmonary imaging.
4DMedical Shares Jump After UC San Diego Health Deploys CT:VQ
4DMedical Limited (ASX: 4DX) shares jumped 16% after UC San Diego Health started using its CT:VQ respiratory imaging technology in clinical practice, becoming the fourth major US academic medical centre to adopt the platform since FDA clearance. At the time of writing, this adoption underscores accelerating traction for CT:VQ in cutting-edge pulmonary diagnostics.
What’s Driving the Momentum?
CT:VQ is a contrast-free lung imaging solution that transforms routine chest CT scans into detailed ventilation and perfusion maps without the need for contrast agents or radioactive tracers, making advanced lung function insights more accessible. After earning FDA 510(k) clearance in September 2025, CT:VQ has gradually gained clinical endorsements from leading US institutions. UC San Diego Health’s structured launch — initially at introductory pricing through March 2026 before full commercial terms — marks a significant step in its commercial rollout.
Top Hospitals Lend Weight to CT:VQ
With UC San Diego Health coming on board, CT:VQ is now in use at four leading US academic medical centres, including Stanford University, the University of Miami and the Cleveland Clinic. These institutions are pivotal reference sites in validating and expanding the technology’s footprint across the US healthcare system. That momentum reflects strong confidence in CT:VQ’s potential to set a new standard of care for pulmonary imaging, offering clinicians a high-resolution, efficient alternative to traditional nuclear ventilation–perfusion scans.
What This Means for 4DMedical’s Future
Investors and industry watchers see this clinical endorsement as a strategic win for 4DMedical, with growing adoption signalling broader market acceptance and potential revenue growth. At the time of writing, the company’s stock reaction highlights the market’s optimism about CT:VQ’s commercial prospects and its role in redefining how lung disease is diagnosed and monitored.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Has 4DMedicals Stock Skyrocketed Again on Big Clinical Win?
Highlights:
4DMedical Shares Jump After UC San Diego Health Deploys CT:VQ
4DMedical Limited (ASX: 4DX) shares jumped 16% after UC San Diego Health started using its CT:VQ respiratory imaging technology in clinical practice, becoming the fourth major US academic medical centre to adopt the platform since FDA clearance. At the time of writing, this adoption underscores accelerating traction for CT:VQ in cutting-edge pulmonary diagnostics.
What’s Driving the Momentum?
CT:VQ is a contrast-free lung imaging solution that transforms routine chest CT scans into detailed ventilation and perfusion maps without the need for contrast agents or radioactive tracers, making advanced lung function insights more accessible. After earning FDA 510(k) clearance in September 2025, CT:VQ has gradually gained clinical endorsements from leading US institutions. UC San Diego Health’s structured launch — initially at introductory pricing through March 2026 before full commercial terms — marks a significant step in its commercial rollout.
Top Hospitals Lend Weight to CT:VQ
With UC San Diego Health coming on board, CT:VQ is now in use at four leading US academic medical centres, including Stanford University, the University of Miami and the Cleveland Clinic. These institutions are pivotal reference sites in validating and expanding the technology’s footprint across the US healthcare system. That momentum reflects strong confidence in CT:VQ’s potential to set a new standard of care for pulmonary imaging, offering clinicians a high-resolution, efficient alternative to traditional nuclear ventilation–perfusion scans.
What This Means for 4DMedical’s Future
Investors and industry watchers see this clinical endorsement as a strategic win for 4DMedical, with growing adoption signalling broader market acceptance and potential revenue growth. At the time of writing, the company’s stock reaction highlights the market’s optimism about CT:VQ’s commercial prospects and its role in redefining how lung disease is diagnosed and monitored.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au